T2 Biosystems, Inc. has formally requested the Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on May 28, 2024. The company seeks to have the registration statement become effective by 4:30 p.m. Washington D.C. time on June 4, 2024, or as soon as possible thereafter. This request was made under Rule 461(a) of the Securities Act of 1933, as amended. T2 Biosystems has asked to be notified of the registration's effectiveness via a phone call to N. Danny Shulman of Latham & Watkins LLP and also expects a written confirmation. John Sperzel, President, CEO, and Chairman of the Board of T2 Biosystems, signed the request.

T2 Biosystems, Inc. has formally requested the Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on May 28, 2024. The company seeks to have the registration statement become effective by 4:30 p.m. Washington D.C. time on June 4, 2024, or as soon as possible thereafter. This request was made under Rule 461(a) of the Securities Act of 1933, as amended. T2 Biosystems has asked to be notified of the registration's effectiveness via a phone call to N. Danny Shulman of Latham & Watkins LLP and also expects a written confirmation. John Sperzel, President, CEO, and Chairman of the Board of T2 Biosystems, signed the request.